The subsequent phase 2a/2b Brightline-2 trial (NCT05512377) is ongoing to further study the safety and efficacy of BI 907828 monotherapy in patients with locally advanced or metastatic MDM2-amplified, TP53 wild-type CCA. Here, TP53 is linked to cholangiocarcinoma.